Novel molecular therapies in hepatocellular carcinoma

S Faivre, M Bouattour, E Raymond - Liver International, 2011 - Wiley Online Library
The approval of sorafenib as the standard of care (SOC) for advanced hepatocellular
carcinoma (HCC) fostered interest to further evaluate several other targeted therapies and …
被引用次数：49 相关文章

Novel molecular therapies in hepatocellular carcinoma

S Faivre, M Bouattour, E Raymond - Liver International, 2011 - infona.pl
The approval of sorafenib as the standard of care (SOC) for advanced hepatocellular
carcinoma (HCC) fostered interest to further evaluate several other targeted therapies and …

Novel molecular therapies in hepatocellular carcinoma

S Faivre, M Bouattour… - … : official journal of the …, 2011 - pubmed.ncbi.nlm.nih.gov
The approval of sorafenib as the standard of care (SOC) for advanced hepatocellular
carcinoma (HCC) fostered interest to further evaluate several other targeted therapies and …
[PDF] academia.edu

[PDF][PDF] Novel molecular therapies in hepatocellular carcinoma

S Faivre, M Bouattour, E Raymond - Liver International, 2010 - academia.edu
The approval of sorafenib as the standard of care (SOC) for advanced hepatocellular
carcinoma (HCC) fostered interest to further evaluate several other targeted therapies and …

Novel molecular therapies in hepatocellular carcinoma.

S Faivre, M Bouattour, E Raymond - Liver International, 2011 - search.ebscohost.com
The approval of sorafenib as the standard of care (SOC) for advanced hepatocellular
carcinoma (HCC) fostered interest to further evaluate several other targeted therapies and …